Aims
To evaluate the equity and effectiveness of Australian services for the early detection of breast cancer in women under 50.
Methods
We summarised breast cancer burden in women <50, mapped service availability, utilisation and outcomes, and analysed related guidelines and policies.
Results
Around 20% of Australian breast cancers are diagnosed in women <50; incidence has increased by 50% over the last 20 years.1 Breast cancer is the second-highest disease burden in Australian women aged 40-49,2 with poorer relative survival compared to older women.3 Early detection saves lives and reduces treatment intensity.4
BreastScreen Australia is available but not targeted to women aged 40-49. Although these services comprise around 10% of BreastScreen episodes, they are not subject to the same level of quality assurance monitoring in place for the target age group (50-74).5 As recommended by the ROSA-Breast project,6 risk-adjusted entry age may be warranted, noting that many countries start screening at 45 (as per European Breast Guidelines7) or age 40 (as per WHO recommendations8).
Outside BreastScreen, different guidelines for referring and managing younger women considered at-risk or symptomatic (e.g. RACGP ‘Red Book’, RANZCR statements, eviQ, Medicare Schedule) mean that women’s pathways to early diagnosis depend on where they live and who they see, with an overreliance on patient-initiated action and capacity for out-of-pocket costs. Qualitative studies show this generates confusion for clinicians and patients9, and disparities related to health literacy and socio-economic status.
Current health data collection and reporting limits our capacity to assess the population-level clinical and cost effectiveness of available services for early detection of breast cancer in younger women.
Conclusions
National Australian clinical guidelines for the early detection of breast cancer would help reduce inequities for women <50 and increase our capacity to evaluate and make evidence-based improvements to these health services.